A randomised, placebo-controlled, double-blind trial to assess the safety and glucose-lowering efficacy of VVP808 compared to placebo in participants with Type 2 diabetes.

Trial Profile

A randomised, placebo-controlled, double-blind trial to assess the safety and glucose-lowering efficacy of VVP808 compared to placebo in participants with Type 2 diabetes.

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Methazolamide (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Verva Pharmaceuticals
  • Most Recent Events

    • 08 Jun 2016 Last checked against Australian New Zealand Clinical Trials Registry.
    • 20 Jul 2015 Primary endpoint (Reduction in HbA1c from baseline after 24 weeks) has been met according to a Verva Pharmaceuticals media release.
    • 20 Jul 2015 Status changed from recruiting to completed according to a Verva Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top